Diabetic Neuropathies
Conditions
Keywords
peripheral neuropathy, Diabetic neuropathy, pain, diabetes, extremities, neuropathy, diabetic
Brief summary
The purpose of this study is to explore the pain-reieiving effects and safety of tramadol HCl/acetaminophen as compared to placebo in patients experiencing painful diabetic neuropathy. Treatment of neuropathic pain often requires the use of more than one medication. The pain-relieving potential of tramadol HCl/acetaminophen for the treatment of painful diabetic neuropathy comes from the multiple mechanisms of action in this combination pain medication. Patients who experience painful diabetic neuropathy will be enrolled in this study.
Detailed description
Previous studies have shown that tramadol HCl is effective in painful diabetic neuropathy. The treatment of neuropathic pain often requires the use of more than one medication, working through different mechanisms of action, to provide the best pain relief. The pain-relieving potential of tramadol HCl /acetaminophen for the treatment of painful diabetic neuropathy comes from the multiple mechanisms of action in this combination pain medication. This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study. Patients who experience painful diabetic neuropathy will be enrolled. There will be a period of up to 3 weeks during which patients will stop taking medications not allowed by the study. A 7-day baseline period will follow, during which time patients will call into an Interactive Voice Response (IVR) system every night at bedtime to record daily assessments including average daily pain and sleep interference. Patients who enter the double-blind portion of the study will be randomized (like with the toss of a coin) to receive either tramadol HCl/acetaminophen or placebo. The dose of tramadol HCl/acetaminophen or placebo will be gradually increased until the doctor determines the patient is taking an adequate dose; up to 1 or 2 tablets 4 times per day, but not more than 8 tablets per day. Every night at bedtime during the double-blind phase, patients will call the IVR system to report assessments of average daily pain, sleep interference and the number of tablets of study medication taken that day. At the end of the study, patients will be tapered off their study medication. The objective of this study is to compare the analgesic effectiveness and safety of tramadol HCl/acetaminophen versus placebo for the treatment of painful diabetic neuropathy. 1 or 2 tramadol HCl (37.5 milligrams)/acetaminophen (325 milligrams) combination tablets or matching placebo by mouth up to 4 times a day for 66 days
Interventions
DRUGtramadol, acetaminophen
Sponsors
PriCara, Unit of Ortho-McNeil, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of diabetic neuropathy in both lower extremities * Lower extremity pain for at least 3 months * Stable treatment of diabetes with drugs or diet for at least 3 months * Documented history of Type I or II diabetes with current treatment control (glycosylated hemoglobin A1c of \<10%) * Documented daily pain on at least 4 of 7 days during baseline period (pain rated at least 5 on scale of 11) * In generally good health * If female of childbearing potential, using acceptable method of birth control
Exclusion criteria
* No failed trials of tramadol HCl or tramadol HCl/acetaminophen * No participation in more than 2 clinical trials for treatment of neuropathic pain * No more than 2 failed trials of medications for neuropathic pain * No use of prohibited concomitant medications * No peripheral neuropathy caused by condition other than diabetes * No other pain more severe than neuropathic pain * No progressive or degenerative neurological disorder * No painful peripheral diabetic neuropathy for \> 10 years * No kidney or liver dysfunction * Not pregnant or breast-feeding * No unstable medical disease * No clinically significant medical conditions * No condition that might affect the way the body absorbs or processes the study drug * No history of suicide attempt/tendencies * No major psychiatric disorder in past 6 months * No history of drug or alcohol abuse/dependance in the past 2 years * No amputations * No active infection of the lower extremity * No active foot ulcer * No use of an investigational drug in past 30 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the average of daily pain score recorded in the IVR system from baseline to the patient's final week of treatment with study medication. | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy measured by Brief Pain Inventory, Visual Analogue Scale, Short-Form McGill Pain Questionnaire, Profile of Mood States, SF-36 Health Survey, Physician and Subject Global Impression of Change, average daily sleep interference | — |
Outcome results
None listed